Prostate Cancer (MSK, 2024)

Overview

Large single-center retrospective cohort of 2,257 prostate cancer (PRAD) patients treated at Memorial Sloan Kettering Cancer Center from April 2015 to February 2021, with 3,244 tumors sequenced by MSK-IMPACT. Designed to characterize MSI-H/dMMR and TMB-H/MSS prostate cancers and evaluate their response to immune checkpoint blockade. Data deposited in cBioPortal as prostate_msk_2024. PMID:38949888

Composition

  • 2,257 patients; 3,244 tumors sequenced with MSK-IMPACT. PMID:38949888
  • MSI-H/dMMR: 63 (2.8%); TMB-H/MSS: 33 (1.5%); TMB-L/MSS: 2,161 (95.7%). PMID:38949888
  • WES performed on 48 tumor samples (20 MSI-H/dMMR, 28 TMB-H/MSS) via recapture of MSK-IMPACT libraries. PMID:38949888

Assays / panels (linked)

Papers using this cohort

  • PMID:38949888 — Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer.

Notable findings derived from this cohort

  • MSI-H/dMMR tumors had significantly higher TMB than TMB-H/MSS (median 41 vs. 15 mut/Mb, P<0.01). Both MSI-H/dMMR (62%) and TMB-H/MSS (59%) tumors more commonly Gleason grade group 5. PMID:38949888
  • ICB response in MSI-H/dMMR (n=27): 45% RECIST ORR (including 2 CRs, 7 PRs); 65% PSA50 response. In TMB-H/MSS (n=8): 0% RECIST response; 50% PSA50 response. PMID:38949888
  • Median rPFS tended to favor MSI-H/dMMR vs. TMB-H/MSS (38 vs. 7 months, HR 2.13, P=0.14). PMID:38949888
  • WES: MSI-H/dMMR tumors had significantly higher neoantigen burden (11.1 vs. 6.8, P=0.011) and indel burden vs. TMB-H/MSS. PMID:38949888

Sources

This page was processed by entity-page-writer on 2026-04-11.